Related Experiment Videos
Microbial factors in inflammatory bowel disease
Richard J Farrell1, J Thomas LaMont
1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Dana 501, 330 Brookline Avenue, Boston, MA 02115, USA. rfarrell@caregroup.harvard.edu
Gastroenterology Clinics of North America
|July 19, 2002
Summary
Microbial factors are intimately involved in Inflammatory Bowel Disease (IBD) pathogenesis, likely involving genetically determined immune responses to gut bacteria. Further research into microflora-targeted therapies like probiotics is crucial for IBD treatment.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- The exact cause of Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), remains unclear, with ongoing debate about the roles of genetics, microbes, and immune responses.
- While specific infectious agents haven't been confirmed as direct causes, commensal enteric bacteria and their products are strongly implicated in IBD initiation, perpetuation, and complications.
Purpose of the Study:
- To explore the intricate connection between the gut microbiome and Inflammatory Bowel Disease (IBD) pathogenesis.
- To highlight the need for rigorous clinical trials investigating microflora-directed therapies for IBD.
Main Methods:
- Review of existing research, with a focus on animal models demonstrating genetically determined immune dysregulation in response to luminal antigens.
- Analysis of the potential of antibiotics and probiotics in modulating the gut flora for therapeutic benefit.
Main Results:
- Animal models strongly suggest that IBD arises from a genetically influenced imbalance in the mucosal immune response to normal gut bacteria.
- Commensal bacteria are identified as key triggers for IBD, disease reactivation, septic complications in CD, and extraintestinal manifestations.
Conclusions:
- Microbial factors are undeniably central to IBD pathogenesis, necessitating a shift towards therapies targeting the gut flora.
- Future research should focus on mechanisms of bacterial tolerance and the beneficial effects of probiotics to identify novel therapeutic targets for IBD.